MRSN - Mersana Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
MRSN price evolution
MRSN
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $174.56 | $186.28 | $128.73 | $122.83 |
| Short term investments | $34.52 | $54.7 | $157.86 | $151.09 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $214.06 | $249.74 | $297.09 | $281.81 |
| Long term investments | ||||
| Property, plant & equipment | $11.53 | $12.69 | $13.4 | $13.8 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12 | $13.17 | $13.91 | $14.39 |
| Total investments | $34.52 | $54.7 | $157.86 | $151.09 |
| Total assets | $226.06 | $262.9 | $311 | $296.19 |
| Current liabilities | ||||
| Accounts payable | $7.32 | $12.95 | $16.92 | $18.16 |
| Deferred revenue | $125.31 | $133.1 | $134.7 | $144.35 |
| Short long term debt | $5.33 | $3.14 | $3.02 | $2.9 |
| Total current liabilities | $63.64 | $67.93 | $74.92 | $83.4 |
| Long term debt | $28.3 | $31.2 | $32.01 | $32.78 |
| Total noncurrent liabilities | $125.52 | $142.78 | $146.28 | $148.5 |
| Total debt | $33.63 | $34.34 | $35.03 | $35.68 |
| Total liabilities | $189.16 | $210.71 | $221.2 | $231.9 |
| Shareholders' equity | ||||
| Retained earnings | -$826.36 | -$806.82 | -$765.16 | -$710.85 |
| Other shareholder equity | $0.01 | $0 | -$0.05 | $0.01 |
| Total shareholder equity | $36.9 | $52.2 | $89.8 | $64.29 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $174.56 | $128.88 | $177.95 | $255.09 |
| Short term investments | $34.52 | $151.83 | ||
| Net receivables | $30 | |||
| Inventory | ||||
| Total current assets | $214.06 | $319.22 | $188.9 | $258.58 |
| Long term investments | ||||
| Property, plant & equipment | $11.53 | $14.46 | $14.86 | $12.67 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12 | $15.12 | $17.21 | $14.82 |
| Total investments | $34.52 | $151.83 | ||
| Total assets | $226.06 | $334.34 | $206.11 | $273.4 |
| Current liabilities | ||||
| Accounts payable | $7.32 | $13.95 | $12.32 | $8.34 |
| Deferred revenue | $125.31 | $147.65 | $3.94 | $3.99 |
| Short long term debt | $5.33 | $2.8 | $2.3 | $1.44 |
| Total current liabilities | $63.64 | $91.53 | $47.52 | $30 |
| Long term debt | $28.3 | $25.13 | $35.87 | $15.13 |
| Total noncurrent liabilities | $125.52 | $150.75 | $36.85 | $15.31 |
| Total debt | $33.63 | $36.3 | $38.18 | $16.57 |
| Total liabilities | $189.16 | $242.28 | $84.37 | $45.31 |
| Shareholders' equity | ||||
| Retained earnings | -$826.36 | -$654.69 | -$450.48 | -$280.42 |
| Other shareholder equity | $0.01 | -$0.15 | ||
| Total shareholder equity | $36.9 | $92.06 | $121.74 | $228.09 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10.7 | $7.7 | $10.65 | $7.8 |
| Cost of revenue | ||||
| Gross Profit | $10.7 | $7.7 | $10.65 | $7.8 |
| Operating activities | ||||
| Research & development | $21.5 | $30.53 | $48.97 | $47.27 |
| Selling, general & administrative | $10.13 | $12.89 | $18.19 | $18.33 |
| Total operating expenses | $32.13 | $51.64 | $67.16 | $65.6 |
| Operating income | -$21.43 | -$43.94 | -$56.5 | -$57.8 |
| Income from continuing operations | ||||
| EBIT | -$18.5 | -$40.64 | -$53.28 | -$55.18 |
| Income tax expense | ||||
| Interest expense | $1.05 | $1.02 | $1.02 | $0.98 |
| Net income | ||||
| Net income | -$19.54 | -$41.66 | -$54.31 | -$56.16 |
| Income (for common shares) | -$19.54 | -$41.66 | -$54.31 | -$56.16 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.85 | $26.58 | $0.04 | $0.83 |
| Cost of revenue | ||||
| Gross Profit | $36.85 | $26.58 | $0.04 | $0.83 |
| Operating activities | ||||
| Research & development | $148.27 | $173.38 | $132.01 | $67.04 |
| Selling, general & administrative | $59.54 | $56.96 | $36.89 | $21.9 |
| Total operating expenses | $216.53 | $230.35 | $168.9 | $88.94 |
| Operating income | -$179.67 | -$203.77 | -$168.86 | -$88.11 |
| Income from continuing operations | ||||
| EBIT | -$167.6 | -$200.88 | -$168.79 | -$87.69 |
| Income tax expense | ||||
| Interest expense | $4.07 | $3.33 | $1.27 | $0.36 |
| Net income | ||||
| Net income | -$171.67 | -$204.21 | -$170.06 | -$88.05 |
| Income (for common shares) | -$171.67 | -$204.21 | -$170.06 | -$88.05 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$19.54 | -$41.66 | -$54.31 | -$56.16 |
| Operating activities | ||||
| Depreciation | $3.23 | $0.43 | $0.32 | $0.32 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.08 | $4 | $6.64 | $6.41 |
| Total cash flows from operations | -$31.96 | -$46.08 | -$61.83 | -$29 |
| Investing activities | ||||
| Capital expenditures | -$0.39 | -$0.47 | -$0.4 | -$0.91 |
| Investments | $20.53 | $104.25 | -$5.04 | $2.31 |
| Total cash flows from investing | $20.15 | $103.78 | -$5.44 | $1.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.16 | -$0.08 | $73.25 | $21.76 |
| Net borrowings | -$0.07 | -$0.07 | -$0.07 | -$0.21 |
| Total cash flows from financing | $0.09 | -$0.15 | $73.18 | $21.55 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$11.72 | $57.55 | $5.91 | -$6.06 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$171.67 | -$204.21 | -$170.06 | -$88.05 |
| Operating activities | ||||
| Depreciation | $4.3 | $0.93 | $0.85 | $1.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $21.14 | $21.52 | $18.41 | $7.17 |
| Total cash flows from operations | -$168.88 | -$49.36 | -$139.99 | -$74.7 |
| Investing activities | ||||
| Capital expenditures | -$2.17 | -$2.2 | -$0.65 | -$0.47 |
| Investments | $122.05 | -$150.52 | $37.5 | |
| Total cash flows from investing | $119.88 | -$152.72 | -$0.65 | $37.03 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $95.09 | $153.29 | $45.56 | $230.72 |
| Net borrowings | -$0.41 | -$0.27 | $18.34 | -$0.31 |
| Total cash flows from financing | $94.67 | $153.02 | $63.65 | $230.41 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $45.68 | -$49.06 | -$76.99 | $192.74 |
News
Fundamentals
| Market cap | $403.18M |
|---|---|
| Enterprise value | $262.25M |
| Shares outstanding | 120.71M |
| Revenue | $36.85M |
|---|---|
| EBITDA | -$163.30M |
| EBIT | -$167.60M |
| Net Income | -$171.67M |
| Revenue Q/Q | -27.14% |
| Revenue Y/Y | 38.65% |
| P/E ratio | -2.35 |
|---|---|
| EV/Sales | 7.12 |
| EV/EBITDA | -1.61 |
| EV/EBIT | -1.56 |
| P/S ratio | 10.94 |
| P/B ratio | 10.93 |
| Book/Share | 0.31 |
| Cash/Share | 1.45 |
| EPS | -$1.42 |
|---|---|
| ROA | -62.64% |
| ROE | -282.36% |
| Debt/Equity | 5.13 |
|---|---|
| Net debt/EBITDA | -0.09 |
| Current ratio | 3.36 |
| Quick ratio | 3.36 |